About Immunomic Therapeutics
Immunomic Therapeutics is a company based in Rockville (United States) founded in 2005. It operates as a HealthTech. Immunomic Therapeutics has raised $104.44 million across 14 funding rounds from investors including NIH, HHS and HLB. Immunomic Therapeutics offers products and services including ITI-1000, ITI-1001, and ITI-3000. Immunomic Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immunomic Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$104.44 M (USD)
in 14 rounds
-
Latest Funding Round
$6.5 M (USD), Series B
May 29, 2025
-
Investors
NIH
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immunomic Therapeutics
Immunomic Therapeutics offers a comprehensive portfolio of products and services, including ITI-1000, ITI-1001, and ITI-3000. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A dendritic cell therapy for glioblastoma multiforme treatment.
An off-the-shelf immunotherapy targeting CMV-associated antigens.
A plasmid DNA vaccine for Merkel cell carcinoma.
Unlock access to complete
Unlock access to complete
Funding Insights of Immunomic Therapeutics
Immunomic Therapeutics has successfully raised a total of $104.44M across 14 strategic funding rounds. The most recent funding activity was a Series B round of $6.5 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Series B — $6.5M
-
First Round
First Round
(16 Aug 2011)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Series B - Immunomic Therapeutics | Valuation |
investors |
|
| Jan, 2024 | Amount | Series B - Immunomic Therapeutics | Valuation |
investors |
|
| Jan, 2021 | Amount | Series B - Immunomic Therapeutics | Valuation | HLB |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immunomic Therapeutics
Immunomic Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and HLB. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Accredited investors are networked for private equity funding opportunities.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in life sciences technologies.
|
Founded Year | Domain | Location | |
|
An angel investor group focused on life science companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immunomic Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immunomic Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunomic Therapeutics Comparisons
Competitors of Immunomic Therapeutics
Immunomic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunomic Therapeutics
Frequently Asked Questions about Immunomic Therapeutics
When was Immunomic Therapeutics founded?
Immunomic Therapeutics was founded in 2005 and raised its 1st funding round 6 years after it was founded.
Where is Immunomic Therapeutics located?
Immunomic Therapeutics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Is Immunomic Therapeutics a funded company?
Immunomic Therapeutics is a funded company, having raised a total of $104.44M across 14 funding rounds to date. The company's 1st funding round was a Series B of $77.73M, raised on Aug 16, 2011.
What does Immunomic Therapeutics do?
Immunomic Therapeutics, Inc. is involved in pioneering nucleic acid immunotherapy platforms through its proprietary UNITE technology. The company is focused on oncology, with potential applications in cancer, allergies, animal health, and infectious diseases. Solutions are developed to leverage the bodys natural biochemistry for broad immune responses, targeting conditions like glioblastoma multiforme and Merkel cell carcinoma. Research and clinical trials are conducted to explore and enhance immune responses in various tumor types.
Who are the top competitors of Immunomic Therapeutics?
Immunomic Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Immunomic Therapeutics offer?
Immunomic Therapeutics offers ITI-1000, ITI-1001, and ITI-3000.
Who are Immunomic Therapeutics's investors?
Immunomic Therapeutics has 8 investors. Key investors include NIH, HHS, HLB, SBIR, and Keiretsu Forum.